Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.53 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | BLVRB | P30043 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17915624 | 0.84 | KMO (0.59) | NPC1RAB9AL3MBTL1NR1H4DGAT1 | |
| SCHEMBL935473 | 0.83 | PRKD1 (0.67) | NPC1RAB9APRKD1CHEK1MAPT | |
| SCHEMBL12171569 | 0.80 | NPC1 (0.76) | NPC1RAB9AL3MBTL1NR1H4MAPT | |
| SCHEMBL4871450 | 0.80 | NR1H4 (0.68) | NPC1RAB9AL3MBTL1NR1H4MAPT | |
| SCHEMBL1675638 | 0.78 | TTR (0.46) | NPC1RAB9ACHEK1MAPTMAOA | |
| SCHEMBL4876270 | 0.77 | NPC1 (0.80) | NPC1RAB9AL3MBTL1NR1H4MAPT | |
| SCHEMBL4875653 | 0.77 | NPC1 (0.67) | NPC1RAB9AL3MBTL1NR1H4MAPT | |
| SCHEMBL1430178 | 0.76 | NR1H4 (0.68) | NPC1RAB9AL3MBTL1NR1H4MAPT | |
| SCHEMBL12171518 | 0.76 | NPC1 (0.67) | NPC1RAB9AL3MBTL1NR1H4MAPT | |
| SCHEMBL998233 | 0.76 | PRKD1 (0.74) | PRKD1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432293-B2 | Heterocyclic compounds useful as Nurr-1 activators | NOVARTIS AG (CH) | 2008-10-07 | — | — | US | disclosed |
| US-20060089365-A1 | Heterocyclic compounds useful as nurr-1 activators | NOVARTIS AG (CH) | 2006-04-27 | — | — | US | disclosed |
| EP-1597243-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS | Novartis AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072050-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089365-A1 | Heterocyclic compounds useful as nurr-1 activators | NCOR1, NCOR2, NR4A1 | NPC1 620/4885RAB9A 2603/4885L3MBTL1 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.